BioNTech收缩CAR-T战线 裁员63人

Core Viewpoint - BioNTech is scaling back its CAR-T therapy operations in response to underwhelming results from early cancer trials, leading to layoffs at its Maryland facility [1] Group 1 - BioNTech plans to reduce the production scale of its CAR-T therapy at its first U.S. facility due to disappointing trial outcomes [1] - The company will lay off 63 employees, primarily from the cell therapy technical operations team at its Gaithersburg, Maryland site [1] - The layoffs are expected to take place by the end of summer this year [1]